Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apatinib combined with oxaliplatin for platinum-resistant recurrent ovarian cancer
ChiCTR-OPC-17013602Phase 4Not yet recruiting
- Sponsor
- Xinqiao Hospital
- Start
- Dec 2017
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of Rivoceranib and oxaliplatin in ovarian cancer, sponsored by Xinqiao Hospital. Primary endpoints: progression-free survival, adverse events and 1 more. Planned start Dec 2017; status: not yet recruiting.
02
Drugs
Rivoceraniboxaliplatin
03
Conditions
ovarian cancer
Beyond the preview
Go deeper on ChiCTR-OPC-17013602.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-OPC-17013602.